Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis — AI Research | MarketCI

PTGX

Market Closed

Protagonist Therapeutics, Inc.

NASDAQHealthcare Biotechnology

132 employees

CEO: Dinesh V. Patel

Founded: 2016

$136.11

+$0.00(+NaN%)

Market Cap

8.75B

Beta

1.79

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

PTGX Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for PTGX built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Strong Sell

Pass %

42.86%

Score

3/7

Fair Value Estimate

Cash flow analysis • Multiple methods

-$9.63

AI Price Target

Machine learning • Price prediction

$129.53

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$3.63

Financial Health

Bankruptcy risk assessment

99.18

Quality Score

Financial strength rating

1.00

AI Investment Grade

Deep analysis of filings & news

75.00

Key Investment Highlights

Important factors affecting PTGX investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

47.50% Poor

Conditions Met

19.00/40.00

Due Diligence Score

47.50%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Fail
	Pass
	Fail
	Fail
	Fail

Showing 1 to 6 of 46 conditions